Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics
2 型糖尿病:了解其早期驱动因素和治疗之路
基本信息
- 批准号:10682747
- 负责人:
- 金额:$ 1.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-05 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AbateAddressAffectBasic ScienceBeta CellCareer MobilityClassificationCollaborationsCommunicationComplications of Diabetes MellitusDevelopmentDiabetes MellitusDiagnosisDiseaseEarly DiagnosisEducationEducational workshopEventFailureFutureGlucoseGlycosylated hemoglobin AGrowthHomeostasisIndustrializationInsulin ResistanceInterventionKnowledgeLearningLegal patentLifeMeasuresMetabolicMetabolic DiseasesMethodologyMolecularNon-Insulin-Dependent Diabetes MellitusObesityOrganOutcomeParticipantPathogenesisPathway interactionsPatientsResearchResearch PersonnelRetinal DiseasesScientistStructure of beta Cell of isletTechnologyTherapeuticThinkingTimeTranslational ResearchTreatment outcomeVisionWorkcareerclinical practicecomorbiditydesigndiabetes mellitus therapydiabetes pathogenesisimprovedinsightinterestmortalitymultidisciplinarynext generationnoveloff-patentpostersprecision medicinepreventsymposiumtherapeutically effectivetreatment and outcome
项目摘要
ABSTRACT
Support is requested for a Keystone Symposia conference entitled Type 2 Diabetes: Understanding its Early
Drivers and the Road to Therapeutics, organized by Drs. Christopher Rhodes, Lora Heisler, and Martin Myers.
The conference will be held in Palm Springs, CA from May 1 - 4, 2023.
Early detection and consequential intervention are key to good treatment outcomes and avoidance of
complications for most diseases. Arguably, this may not be the case for Type-2 diabetes (T2D) where
measures of elevated glucose and HbA1C, historically related to a predicted onset of retinopathy, occur too
late in the pathogenesis of the disease. This makes the need for improved markers of T2D necessary to
better diagnose and treat this prevalent disease at early stages. With the advent of precision medicine, now is
the time to re-examine the pathogenesis of type 2 (pre)diabetes at the molecular level. However, questions
the field remain, such as: 1. Which subsets of T2D define the rate of progression to certain diabetes
complications; 2. Can early molecular drivers of the disease be better identified; 3. What factors contribute to
dysfunctional inter-organ communication and altered metabolic homeostasis; 4. Does pancreatic ß-cell failure
really define the disease; and 5. If detected early enough, can we envision ways to reverse, or even prevent
T2D? The silver lining is that with several commonly used T2D therapies coming off patent soon, this may just
be conceivable. Nonetheless, there also remains a need for more effective therapeutic approaches, not just
for T2D, but also for its comorbidities. Therefore, this Keystone Symposia conference will examine the current
knowledge of T2D pathogenesis and the therapeutic landscape with a vision towards earlier diagnosis, as well
as, towards more effective and tailored T2D treatment regime(s) that could also prevent (or significantly delay)
the pathway to complications and comorbidities.
摘要
要求支持一个关键研讨会会议题为2型糖尿病:了解其早期
司机和治疗之路,由克里斯托弗罗兹博士,劳拉海斯勒和马丁迈尔斯组织。
会议将于2023年5月1日至4日在加州棕榈泉举行。
早期发现和相应的干预是良好治疗结果和避免并发症的关键。
大多数疾病的并发症。可以说,这可能不是2型糖尿病(T2 D)的情况,
血糖和HbA 1C升高的测量也会发生,这在历史上与视网膜病变的预测发作有关
在疾病的发病机制中处于晚期。这使得需要改进的T2 D标志物,
更好地诊断和治疗这种流行病的早期阶段。随着精准医疗的出现,
是时候在分子水平上重新研究2型糖尿病(前驱)的发病机制了。然而,问题
字段保持不变,例如:1. T2 D的哪些子集定义了某些糖尿病的进展率
并发症; 2.疾病的早期分子驱动因素是否可以更好地识别; 3.哪些因素导致
器官间通讯功能障碍和代谢稳态改变; 4.胰腺癌细胞衰竭
真正定义疾病;和5。如果发现得足够早,我们是否可以设想扭转,甚至防止
2型糖尿病?银线是,随着几种常用的T2 D疗法即将关闭专利,这可能只是
可以想象。尽管如此,仍然需要更有效的治疗方法,而不仅仅是
对于T2 D,以及它的合并症。因此,本次Keystone研讨会将审查当前的
T2 D发病机制和治疗前景的知识,以及对早期诊断的愿景,
同样,迈向更有效和更定制的T2 D治疗方案,也可以预防(或显着延迟)
导致并发症和合并症的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERRY L. SHEPPARD其他文献
TERRY L. SHEPPARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERRY L. SHEPPARD', 18)}}的其他基金
Pulmonary Hypertension: State of the Art and Therapeutic Opportunities
肺动脉高压:最新技术和治疗机会
- 批准号:
10682118 - 财政年份:2023
- 资助金额:
$ 1.32万 - 项目类别:
Infections in Pregnancy: PathogenicMechanisms, Experimental Advances and Clinical Strategies
妊娠期感染:致病机制、实验进展和临床策略
- 批准号:
10540260 - 财政年份:2023
- 资助金额:
$ 1.32万 - 项目类别:
Mechanisms of Microbiota-Immune Interactions-Towards the Next Decade
微生物群-免疫相互作用的机制-迈向下一个十年
- 批准号:
10753451 - 财政年份:2023
- 资助金额:
$ 1.32万 - 项目类别:
Long COVID and Post Acute Sequalae of SARS CoV 2 (PASC): Pathogenesis and Treatment
长期新冠肺炎和 SARS CoV 2 (PASC) 急性后遗症:发病机制和治疗
- 批准号:
10749522 - 财政年份:2023
- 资助金额:
$ 1.32万 - 项目类别:
Transposable Elements at the Crossroads of Evolution, Health and Disease
处于进化、健康和疾病十字路口的转座元件
- 批准号:
10750852 - 财政年份:2023
- 资助金额:
$ 1.32万 - 项目类别:
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
传染病、自身免疫和 B 细胞癌症背景下的 B 细胞生物学
- 批准号:
10683443 - 财政年份:2023
- 资助金额:
$ 1.32万 - 项目类别:
Inflammation in the Lung: Friend or Foe in Viral Infections?
肺部炎症:病毒感染的朋友还是敌人?
- 批准号:
10681956 - 财政年份:2023
- 资助金额:
$ 1.32万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 1.32万 - 项目类别:
Research Grant














{{item.name}}会员




